GlassScriptPhysician profile
Aaron J Morgan
NPI 1699901389
$11,299.11
in general payments reported to CMS, 2019-2025
38 companies · $2,658 in 2025
The $2,658 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $746 · 2021: $670 · 2022: $1,498 · 2023: $2,041 · 2024: $2,731 · 2025: $2,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,057 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,057.05 |
| Education | $372.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,267.75 | 2019-2025 | Tremfya, Simponi, Remicade |
| Merz North America, INC. | $1,234.56 | 2019-2022 | |
| Abbvie INC. | $1,182.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $823.04 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $806.03 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $781.50 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $690.28 | 2019-2025 | |
| Galderma Laboratories, L.P. | $617.41 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $469.58 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $459.92 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $405.48 | 2020-2025 | Otezla, Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $366.76 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $341.87 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Integra Lifesciences Corporation | $317.70 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Genzyme Corporation | $262.28 | 2021-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $240.74 | 2023-2025 | Zoryve |
| Pfizer INC. | $188.16 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $154.56 | 2023-2025 | |
| Dermavant Sciences, INC. | $141.14 | 2023-2024 | Vtama |
| Journey Medical Corporation | $69.03 | 2019-2024 | |
| Ucb, INC. | $64.94 | 2023-2025 | Bimzelx |
| Celgene Corporation | $46.57 | 2019 | |
| Dusa Pharmaceuticals, INC. | $45.09 | 2019 | |
| Epi Health, LLC | $41.21 | 2019-2022 | |
| Encore Dermatology INC. | $39.74 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $34.38 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $34.34 | 2024 | Ycanth |
| Almirall LLC | $32.46 | 2024-2025 | Seysara |
| Revance Therapeutics, INC. | $28.35 | 2024 | Daxxify |
| Dermira, INC. | $26.11 | 2019-2020 | |
| Botanix Sb INC | $18.32 | 2025 | Sofdra |
| Mission Pharmacal Company | $15.48 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $14.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Biofrontera INC. | $12.47 | 2020 | |
| Organon LLC | $8.99 | 2025 | Vtama |
| Pierre Fabre Pharmaceuticals, INC. | $3.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.